Phone: 888-558-5227

651-644-8424 Email: getinfo@lktlabs.com

888-558-7329 Fax:

Web: lktlabs.com

Product Information

Product ID 01200

CAS No. 603139-19-1

Chemical Name

Synonym MK0822; MK-0822

Formula $C_{25}H_{27}F_4N_3O_3S$

Formula Wt. 525.56

Melting Point

Purity ≥99%

Solubility DMSO 100 mg/mL (190.27

mM)

Water Insoluble Ethanol Insoluble

Store Temp -20°C

Ship Temp Ambient

Bulk quanitites available upon request

Product ID	Size
O1200	1 mg
O1200	5 mg
O1200	10 mg
O1200	25 mg

Description Odanacatib is an inhibitor of cathepsin K that displays anti-osteoporotic and anti-resorptive activities. Odanacatib protects bone against periapical infection and disease by preventing pathogenic infection, immune responses, and bone erosion. This compound is currently in clinical trials as a potential treatment for osteoporosis, where it inhibits bone resorption and increases bone mineral density.

References Bone HG, Dempster DW, Eisman JA, et al. Odanacatib for the treatment of postmenopausal osteoporosis: development history and design and participant characteristics of LOFT, the Long-Term Odanacatib Fracture Trial. Osteoporos Int. 2015 Feb;26 (2):699-712. PMID: 25432773.

> Hao L, Chen W, McConnell M, et al. A small molecule, Odanacatib, inhibits inflammation and bone loss caused by endodontic disease. Infect Immun. 2015 Jan 12. [Epub ahead of print]. PMID: 25583522.

> Gauthier JY, Chauret N, Cromlish W, et al. The discovery of odanacatib (MK-0822), a selective inhibitor of cathepsin K. Bioorg Med Chem Lett. 2008 Feb 1;18(3):923-8. PMID: 18226527.

Caution: This product is intended for laboratory and research use only. It is not for human or drug use.